Metabolic Reprogramming via Targeting CD38 NADase Augments Adoptive T Cell Therapy

Cell Metab. 2018 Jan 9;27(1):3-5. doi: 10.1016/j.cmet.2017.12.014.

Abstract

One strategy to improve the potency of adoptive T cell therapy is to augment the function and persistence of anti-tumor T cells. In this issue of Cell Metabolism, Chatterjee et al. (2018) demonstrate that intratumoral CD4+ T cell functions and memory can be improved by targeting a CD38-NAD+-Sirt1-Foxo1 metabolic circuit.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • ADP-ribosyl Cyclase 1
  • Cell- and Tissue-Based Therapy
  • Humans
  • NAD
  • NAD+ Nucleosidase*
  • Neoplasms*

Substances

  • NAD
  • NAD+ Nucleosidase
  • ADP-ribosyl Cyclase 1